These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

123 related articles for article (PubMed ID: 9417161)

  • 21. Pemoline-induced abnormal involuntary movements.
    Sallee FR; Stiller RL; Perel JM; Everett G
    J Clin Psychopharmacol; 1989 Apr; 9(2):125-9. PubMed ID: 2723130
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Treatment of attention-deficit/hyperactivity disorder.
    Jadad AR; Boyle M; Cunningham C; Kim M; Schachar R
    Evid Rep Technol Assess (Summ); 1999 Nov; (11):i-viii, 1-341. PubMed ID: 10790990
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Symposium: behavior modification by drugs. II. Psychological effects of stimulant drugs in children with minimal brain dysfunction.
    Conners CK
    Pediatrics; 1972 May; 49(5):702-8. PubMed ID: 4402496
    [No Abstract]   [Full Text] [Related]  

  • 24. Change from Mg-pemoline to bupropion in a 12-year-old boy with attention-deficit hyperactivity disorder.
    Bloomingdale LM
    J Clin Psychopharmacol; 1990 Oct; 10(5):382-3. PubMed ID: 2124222
    [No Abstract]   [Full Text] [Related]  

  • 25. Hepatotoxicity due to pemoline (Cylert): a report of two cases.
    Pratt DS; Dubois RS
    J Pediatr Gastroenterol Nutr; 1990 Feb; 10(2):239-41. PubMed ID: 2303976
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Compliance with FDA recommendations for pemoline.
    Sarkis EH
    J Am Acad Child Adolesc Psychiatry; 2003 Apr; 42(4):383; author reply 383. PubMed ID: 12649623
    [No Abstract]   [Full Text] [Related]  

  • 27. Pemoline effects on children with ADHD: a time-response by dose-response analysis on classroom measures.
    Pelham WE; Swanson JM; Furman MB; Schwindt H
    J Am Acad Child Adolesc Psychiatry; 1995 Nov; 34(11):1504-13. PubMed ID: 8543519
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Methylphenidate use in males with Duchenne muscular dystrophy and a comorbid attention-deficit hyperactivity disorder.
    Lionarons JM; Hellebrekers DMJ; Klinkenberg S; Faber CG; Vles JSH; Hendriksen JGM
    Eur J Paediatr Neurol; 2019 Jan; 23(1):152-157. PubMed ID: 30287260
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Depression following pemoline withdrawal in a hyperactive child.
    Brown RT; Borden KA; Spunt AL; Medenis R
    Clin Pediatr (Phila); 1985 Mar; 24(3):174. PubMed ID: 3971647
    [No Abstract]   [Full Text] [Related]  

  • 30. Pemoline and hepatotoxicity.
    McCurry L; Cronquist S
    Am J Psychiatry; 1997 May; 154(5):713-4. PubMed ID: 9137138
    [No Abstract]   [Full Text] [Related]  

  • 31. Pemoline pharmacokinetics and long term therapy in children with attention deficit disorder and hyperactivity.
    Collier CP; Soldin SJ; Swanson JM; MacLeod SM; Weinberg F; Rochefort JG
    Clin Pharmacokinet; 1985; 10(3):269-78. PubMed ID: 4017397
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Effect on growth in pemoline-treated children with attention deficit disorder.
    Friedmann N; Thomas J; Carr R; Elders J; Ringdahl I; Roche A
    Am J Dis Child; 1981 Apr; 135(4):329-32. PubMed ID: 7211792
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Attention deficit hyperactivity in adults.
    Cubbin S; Leahy A
    Br J Psychiatry; 1998 Apr; 172():366. PubMed ID: 9715347
    [No Abstract]   [Full Text] [Related]  

  • 34. Pemoline-associated fulminant liver failure: testing the evidence for causation.
    Berkovitch M; Pope E; Phillips J; Koren G
    Clin Pharmacol Ther; 1995 Jun; 57(6):696-8. PubMed ID: 7781270
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Gilles de la Tourette's disorder associated with pemoline.
    Mitchell E; Matthews KL
    Am J Psychiatry; 1980 Dec; 137(12):1618-9. PubMed ID: 6933864
    [No Abstract]   [Full Text] [Related]  

  • 36. Medication for attention deficit hyperactivity disorder: commentary and response.
    Faigel HC; Heiligenstein E
    J Am Coll Health; 1996 Jul; 45(1):40-1; discussion 41-2. PubMed ID: 8708265
    [No Abstract]   [Full Text] [Related]  

  • 37. Pemoline-induced Tourette's disorder: a case report.
    Bachman DS
    Am J Psychiatry; 1981 Aug; 138(8):1116-7. PubMed ID: 6942661
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Pemoline therapy in college students with attention deficit hyperactivity disorder: a retrospective study.
    Heiligenstein E; Johnston HF; Nielsen JK
    J Am Coll Health; 1996 Jul; 45(1):35-9. PubMed ID: 8708264
    [TBL] [Abstract][Full Text] [Related]  

  • 39. An open trial of pemoline in drug-dependent delinquents with attention-deficit hyperactivity disorder.
    Riggs PD; Thompson LL; Mikulich SK; Whitmore EA; Crowley TJ
    J Am Acad Child Adolesc Psychiatry; 1996 Aug; 35(8):1018-24. PubMed ID: 8755798
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Relative efficacy of long-acting stimulants on children with attention deficit-hyperactivity disorder: a comparison of standard methylphenidate, sustained-release methylphenidate, sustained-release dextroamphetamine, and pemoline.
    Pelham WE; Greenslade KE; Vodde-Hamilton M; Murphy DA; Greenstein JJ; Gnagy EM; Guthrie KJ; Hoover MD; Dahl RE
    Pediatrics; 1990 Aug; 86(2):226-37. PubMed ID: 2196522
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.